An "Omics" based survey of human colon cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 693, Issue 1-2, 2010, Pages 3-18

  Nambiar, Prashant R ^a   Gupta, Rishi R ^a   Misra, Vikas ^b  

^a PFIZER INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Colon cancer; Colorectal cancer; Metabolomics; Proteomics; Systems biology; Transcriptomics

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ADENOSYLHOMOCYSTEINASE; ALCOHOL DEHYDROGENASE; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE XII; CHAPERONIN; CXCL3 CHEMOKINE; CYCLIN A2; CYCLIN B2; CYCLINE; FORMYLPEPTIDE RECEPTOR; GAMMA GLUTAMYL HYDROLASE; GELSOLIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HERMES ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INITIATION FACTOR 2; INOSINATE DEHYDROGENASE; INTERSTITIAL COLLAGENASE; NEU DIFFERENTIATION FACTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOGLUCOMUTASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD4 PROTEIN; STROMELYSIN 3; TRANSCRIPTION FACTOR SOX9;

ANEUPLOIDY; CANCER STAGING; COLON CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; ELECTROSPRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC ALGORITHM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TUMOR DIFFERENTIATION;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; GENOMICS; HUMANS; METABOLOMICS; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 78049428079     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.07.008     Document Type: Review

References (91)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58(2):71-96.
2. Kahi C.J., Rex D.K., Imperiale T.F. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 2008, 135(2):380-399.
3. Jass J.R. Limitations of the adenoma-carcinoma sequence in colorectum. Clin. Cancer Res. 2004, 10(17):5969-5970. author reply 5970.
4. Hardcastle J.D., Thomas W.M., Chamberlain J., Pye G., Sheffield J., James P.D., Balfour T.W., Amar S.S., Armitage N.C., Moss S.M. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet 1989, 1(8648):1160-1164.
5. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348(9040):1467-1471.
6. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med. 1993, 328(19):1365-1371.
7. Ahlquist D.A., Skoletsky J.E., Boynton K.A., Harrington J.J., Mahoney D.W., Pierceall W.E., Thibodeau S.N., Shuber A.P. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000, 119(5):1219-1227.
8. Chen W.D., Han Z.J., Skoletsky J., Olson J., Sah J., Myeroff L., Platzer P., Lu S., Dawson D., Willis J., et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 2005, 97(15):1124-1132.
9. Dong S.M., Traverso G., Johnson C., Geng L., Favis R., Boynton K., Hibi K., Goodman S.N., D'Allessio M., Paty P., et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J. Natl. Cancer Inst. 2001, 93(11):858-865.
10. Li M., Chen W.D., Papadopoulos N., Goodman S.N., Bjerregaard N.C., Laurberg S., Levin B., Juhl H., Arber N., Moinova H., et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 2009, 27(9):858-863.
11. Gold P., Freedman S.O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 1965, 122(3):467-481.
12. Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn. 2008, 8(3):277-288.
13. Cardoso J., Boer J., Morreau H., Fodde R. Expression and genomic profiling of colorectal cancer. Biochim. Biophys. Acta 2007, 1775(1):103-137.
14. Romero R., Espinoza J., Gotsch F., Kusanovic J.P., Friel L.A., Erez O., Mazaki-Tovi S., Than N.G., Hassan S., Tromp G. The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG 2006, 113(Suppl. 3):118-135.
15. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318(5853):1108-1113.
16. Sjoblom T. Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Curr. Opin. Oncol. 2008, 20(1):66-71.
17. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.
18. Lin J., Gan C.M., Zhang X., Jones S., Sjoblom T., Wood L.D., Parsons D.W., Papadopoulos N., Kinzler K.W., Vogelstein B., et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res. 2007, 17(9):1304-1318.
19. Claudino W.M., Quattrone A., Biganzoli L., Pestrin M., Bertini I., Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 2007, 25(19):2840-2846.
20. Nambiar P.R., Boutin S.R., Raja R., Rosenberg D.W. Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia. Vet. Pathol. 2005, 42(6):735-752.
21. Alon U., Barkai N., Notterman D.A., Gish K., Ybarra S., Mack D., Levine A.J. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(12):6745-6750.
22. Lin Y.M., Furukawa Y., Tsunoda T., Yue C.T., Yang K.C., Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21(26):4120-4128.
23. Notterman D.A., Alon U., Sierk A.J., Levine A.J. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001, 61(7):3124-3130.
24. Lechner S., Muller-Ladner U., Renke B., Scholmerich J., Ruschoff J., Kullmann F. Gene expression pattern of laser microdissected colonic crypts of adenomas with low grade dysplasia. Gut 2003, 52(8):1148-1153.
25. Nosho K., Yamamoto H., Adachi Y., Endo T., Hinoda Y., Imai K. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br. J. Cancer 2005, 92(7):1193-1200.
26. Bertucci F., Salas S., Eysteries S., Nasser V., Finetti P., Ginestier C., Charafe-Jauffret E., Loriod B., Bachelart L., Montfort J., et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004, 23(7):1377-1391.
27. Eschrich S., Yang I., Bloom G., Kwong K.Y., Boulware D., Cantor A., Coppola D., Kruhoffer M., Aaltonen L., Orntoft T.F., et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 2005, 23(15):3526-3535.
28. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst. 2002, 94(7):513-521.
29. Birkenkamp-Demtroder K., Christensen L.L., Olesen S.H., Frederiksen C.M., Laiho P., Aaltonen L.A., Laurberg S., Sorensen F.B., Hagemann R., Ørntoft T.F. Gene expression in colorectal cancer. Cancer Res. 2002, 62(15):4352-4363.
30. Wang Y., Jatkoe T., Zhang Y., Mutch M.G., Talantov D., Jiang J., McLeod H.L., Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 2004, 22(9):1564-1571.
31. Arango D., Laiho P., Kokko A., Alhopuro P., Sammalkorpi H., Salovaara R., Nicorici D., Hautaniemi S., Alazzouzi H., Mecklin J.P., et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005, 129(3):874-884.
32. Barrier A., Boelle P.Y., Lemoine A., Tse C., Brault D., Chiappini F., Lacaine F., Houry S., Huguier M., Flahault A., et al. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis. Colon Rectum 2005, 48(12):2238-2248.
33. Barrier A., Boelle P.Y., Roser F., Gregg J., Tse C., Brault D., Lacaine F., Houry S., Huguier M., Franc B., et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J. Clin. Oncol. 2006, 24(29):4685-4691.
34. Barrier A., Lemoine A., Boelle P.Y., Tse C., Brault D., Chiappini F., Breittschneider J., Lacaine F., Houry S., Huguier M., et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005, 24(40):6155-6164.
35. Barrier A., Roser F., Boelle P.Y., Franc B., Tse C., Brault D., Lacaine F., Houry S., Callard P., Penna C., et al. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 2007, 26(18):2642-2648.
36. Galamb O., Gyorffy B., Sipos F., Spisak S., Nemeth A.M., Miheller P., Tulassay Z., Dinya E., Molnar B. Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. Dis. Markers 2008, 25(1):1-16.
37. Galamb O., Sipos F., Solymosi N., Spisak S., Krenacs T., Toth K., Tulassay Z., Molnar B. Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol. Biomarkers Prev. 2008, 17(10):2835-2845.
38. Komori T., Takemasa I., Yamasaki M., Motoori M., Kato T., Kikkawa N., Kawaguchi N., Ikeda M., Yamamoto H., Sekimoto M., et al. Gene expression of colorectal cancer: preoperative genetic diagnosis using endoscopic biopsies. Int. J. Oncol. 2008, 32(2):367-375.
39. Habermann J.K., Paulsen U., Roblick U.J., Upender M.B., McShane L.M., Korn E.L., Wangsa D., Kruger S., Duchrow M., Bruch H.P., et al. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007, 46(1):10-26.
40. Dalal S.N., Yaffe M.B., DeCaprio J.A. 14-3-3 Family members act coordinately to regulate mitotic progression. Cell Cycle 2004, 3(5):672-677.
41. Forrest A., Gabrielli B. Cdc25B activity is regulated by 14-3-3. Oncogene 2001, 20(32):4393-4401.
42. Jiang K., Pereira E., Maxfield M., Russell B., Goudelock D.M., Sanchez Y. Regulation of Chk1 includes chromatin association and 14-3-3 binding following phosphorylation on Ser-345. J. Biol. Chem. 2003, 278(27):25207-25217.
43. Katayama K., Fujita N., Tsuruo T. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol. Cell. Biol. 2005, 25(13):5725-5737.
44. Samuel T., Weber H.O., Rauch P., Verdoodt B., Eppel J.T., McShea A., Hermeking H., Funk J.O. The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J. Biol. Chem. 2001, 276(48):45201-45206.
45. Gardina P.J., Clark T.A., Shimada B., Staples M.K., Yang Q., Veitch J., Schweitzer A., Awad T., Sugnet C., Dee S., et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006, 7:325.
46. Thorsen K., Sorensen K.D., Brems-Eskildsen A.S., Modin C., Gaustadnes M., Hein A.M., Kruhoffer M., Laurberg S., Borre M., Wang K., et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol. Cell Proteomics 2008, 7(7):1214-1224.
47. Evans G.A. Designer science and the " omic" revolution. Nat. Biotechnol. 2000, 18(2):127.
48. Anderson N.G., Anderson N.L. Twenty years of two-dimensional electrophoresis: past, present and future. Electrophoresis 1996, 17(3):443-453.
49. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975, 250(10):4007-4021.
50. Cho A., Normile D. Nobel prize in chemistry. Mastering macromolecules. Science 2002, 298(5593):527-528.
51. Blattner F.R., Plunkett G., Bloch C.A., Perna N.T., Burland V., Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F., et al. The complete genome sequence of Escherichia coli K-12. Science 1997, 277(5331):1453-1474.
52. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., et al. The sequence of the human genome. Science 2001, 291(5507):1304-1351.
53. Shevchenko A., Jensen O.N., Podtelejnikov A.V., Sagliocco F., Wilm M., Vorm O., Mortensen P., Shevchenko A., Boucherie H., Mann M. Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(25):14440-14445.
54. Issaq H.J. The role of separation science in proteomics research. Electrophoresis 2001, 22(17):3629-3638.
55. Melle C., Ernst G., Schimmel B., Bleul A., Thieme H., Kaufmann R., Mothes H., Settmacher U., Claussen U., Halbhuber K.J., et al. Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005, 129(1):66-73.
56. Yu J.K., Chen Y.D., Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 2004, 10(21):3127-3131.
57. Li J.Q., Xu B.J., Shakhtour B., Deane N., Merchant N., Heslin M.J., Washington K., Coffey R.J., Beauchamp R.D., Shyr Y., et al. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Int. J. Oncol. 2007, 31(1):103-111.
58. Wu C.C., Chen H.C., Chen S.J., Liu H.P., Hsieh Y.Y., Yu C.J., Tang R., Hsieh L.L., Yu J.S., Chang Y.S. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8(2):316-332.
59. Albrethsen J., Bogebo R., Gammeltoft S., Olsen J., Winther B., Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005, 5:8.
60. Habermann J.K., Roblick U.J., Luke B.T., Prieto D.A., Finlay W.J., Podust V.N., Roman J.M., Oevermann E., Schiedeck T., Homann N., et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006, 131(4):1020-1029. quiz 1284.
61. Ward D.G., Suggett N., Cheng Y., Wei W., Johnson H., Billingham L.J., Ismail T., Wakelam M.J., Johnson P.J., Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 2006, 94(12):1898-1905.
62. Fletcher R.H. Carcinoembryonic antigen. Ann. Intern. Med. 1986, 104(1):66-73.
63. Bell A.W., Deutsch E.W., Au C.E., Kearney R.E., Beavis R., Sechi S., Nilsson T., Bergeron J.J., Beardslee T.A., Chappell T., et al. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat. Methods 2009.
64. Rochfort S. Metabolomics reviewed: a new " omics" platform technology for systems biology and implications for natural products research. J. Nat. Prod. 2005, 68(12):1813-1820.
65. Chan E.C., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., Cavill R., Nicholson J.K., Keun H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 2009, 8(1):352-361.
66. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4(7):551-561.
67. Griffin J.L., Kauppinen R.A. Tumour metabolomics in animal models of human cancer. J. Proteome Res. 2007, 6(2):498-505.
68. Mal M., Koh P.K., Cheah P.Y., Chan E.C. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Commun. Mass Spectrom. 2009, 23(4):487-494.
69. Denkert C., Budczies J., Weichert W., Wohlgemuth G., Scholz M., Kind T., Niesporek S., Noske A., Buckendahl A., Dietel M., et al. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol. Cancer 2008, 7:72.
70. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
71. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., Kinoshita T., Saito N., Ochiai A., Tomita M., et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009, 69(11):4918-4925.
72. Backshall A., Alferez D., Teichert F., Wilson I.D., Wilkinson R.W., Goodlad R.A., Keun H.C. Detection of metabolic alterations in non-tumor gastrointestinal tissue of the Apc(Min/+) mouse by (1)H MAS NMR spectroscopy. J. Proteome Res. 2009, 8(3):1423-1430.
73. Braakhuis B.J., Tabor M.P., Kummer J.A., Leemans C.R., Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003, 63(8):1727-1730.
74. Monleon D., Morales J.M., Barrasa A., Lopez J.A., Vazquez C., Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009, 22(3):342-348.
75. Ludwig C., Ward D.G., Martin A., Viant M.R., Ismail T., Johnson P.J., Wakelam M.J., Gunther U.L. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn. Reson. Chem. 2009.
76. Wishart D.S., Lewis M.J., Morrissey J.A., Flegel M.D., Jeroncic K., Xiong Y., Cheng D., Eisner R., Gautam B., Tzur D., et al. The human cerebrospinal fluid metabolome. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 871(2):164-173.
77. Blow N. Metabolomics: biochemistry's new look. Nature 2008, 455(7213):697-700.
78. Kreeger P.K., Lauffenburger D.A. Cancer systems biology: a network modeling perspective. Carcinogenesis 2010, 31(1):2-8.
79. Douglas E.J., Fiegler H., Rowan A., Halford S., Bicknell D.C., Bodmer W., Tomlinson I.P., Carter N.P. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res. 2004, 64(14):4817-4825.
80. Grade M., Hormann P., Becker S., Hummon A.B., Wangsa D., Varma S., Simon R., Liersch T., Becker H., Difilippantonio M.J., et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res. 2007, 67(1):41-56.
81. Hughes T.R., Roberts C.J., Dai H., Jones A.R., Meyer M.R., Slade D., Burchard J., Dow S., Ward T.R., Kidd M.J., et al. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat. Genet. 2000, 25(3):333-337.
82. Hyman E., Kauraniemi P., Hautaniemi S., Wolf M., Mousses S., Rozenblum E., Ringner M., Sauter G., Monni O., Elkahloun A., et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62(21):6240-6245.
83. Masayesva B.G., Ha P., Garrett-Mayer E., Pilkington T., Mao R., Pevsner J., Speed T., Benoit N., Moon C.S., Sidransky D., et al. Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(23):8715-8720.
84. Phillips J.L., Hayward S.W., Wang Y., Vasselli J., Pavlovich C., Padilla-Nash H., Pezullo J.R., Ghadimi B.M., Grossfeld G.D., Rivera A., et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res. 2001, 61(22):8143-8149.
85. Pollack J.R., Sorlie T., Perou C.M., Rees C.A., Jeffrey S.S., Lonning P.E., Tibshirani R., Botstein D., Borresen-Dale A.L., Brown P.O. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(20):12963-12968.
86. Tsafrir D., Bacolod M., Selvanayagam Z., Tsafrir I., Shia J., Zeng Z., Liu H., Krier C., Stengel R.F., Barany F., et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res. 2006, 66(4):2129-2137.
87. Reid J.F., Gariboldi M., Sokolova V., Capobianco P., Lampis A., Perrone F., Signoroni S., Costa A., Leo E., Pilotti S., et al. Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer 2009, 48(11):953-962.
88. Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115(16):3618-3630.
89. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., Kay C., Um I.H., Langdon S., Goryanin I., et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009, 69(16):6713-6720.
90. Mani K.M., Lefebvre C., Wang K., Lim W.K., Basso K., Dalla-Favera R., Califano A. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol. Syst. Biol. 2008, 4:169.
91. Aebersold R., Auffray C., Baney E., Barillot E., Brazma A., Brett C., Brunak S., Butte A., Califano A., Celis J., et al. Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol. Oncol. 2009, 3(1):9-17.